Tempus AI Short Interest Soars to 30.5%
Welcome to this week's installment of "The Short Interest Report" - The Fly's weekly recap of short interest trends among some of the most widely followed high-short-float stocks. Using the data from our partner, which utilizes the latest information from stock lenders to estimate short interest changes for thousands of publicly traded companies, this report will screen for some of biggest changes in short interest as a percentage of free float and days-to-cover ratios while also considering the short interest data on some of the more volatile and heavier-traded names of the week. Based on the availability of data from Ortex, the report tracks the trading period that covers prior Friday through Thursday of this week, excluding holidays. As a basis of comparison for stocks discussed below, the S&P 500 index was up 1.6%, the Nasdaq Composite was up 2.4%, the Russell 2000 index was up 3.3%, the Russell 2000 Growth ETFwas up 4.0% and the Russell 2000 Value ETFwas up 3.3% in the four-day trading session range through May 28.SHORT INTEREST GAINERSOrtex-reported short interest on Tempus AIhad tracked in the 21% to 25% range since the first week of March before jumping this week from 23.3% to 30.5% - the highest level on record. Days-to-cover on the stock also hit its highest print, rising from 4.8 to 6.5, with the bulk of the increase coming on Thursday in spite of the spike in trading volume. Overall, the stock was up 10.3% in the four-day period covered this week, with the rally catalyzed by the announced expansion of indications to the company's Next platform ahead of the 2026 American Society of Clinical Oncology Annual Meeting, prior to Friday's 2% slip. Year-to-date, TempusAI is now down about 15%.Ortex-reported short interest in Figmahad broken out into double-digits in February and continued to rise gradually over the past several months. Over the past month, however, while investors have seemingly gained conviction that the pressure over the post-IPO period may have subsided as the stock price rallied, the accumulation on the bearish side has also accelerated. This week, short interest as a percentage of free float jumped five percentage points to 30.8% - the highest level on record. Days-to-cover on the name similarly turned up, in spite of the spike in trading volume seen after the company's Q1 results in mid-May, rising from 3.3 to 4.2, also a record high. Shares of Figma were up about 9% in the four-day period covered through Thursday. Still, even after Friday's additional 9% jump, the stock remains down by about 32% year-to-date.As discussed here two weeks ago, short positions in Rumblesaw a washout over the last week of April and into the first week of May as shares rebounded from March lows with a rally of about 75%. With the bounce in the stock price accelerating over the past several sessions however, bears are more emboldened by the perception of an overly aggressive valuation. This week, according to Ortex data, short interest as a percentage of free float on Rumble jumped from 20.1% to 27.9% - the highest level in over 14 months - while days-to-cover on the name rose from 8.6 to 9.1. The stock was up 28% in the four-day period covered and has now gained 45% year to date, though shares are giving in to some profit taking on Friday with a 3% decline.SHORT INTEREST DECLINERSOrtex-reported short interest on Bobs Discount Furniturepeaked at a record-high of 28% on May 15 as bears positioned to fade the two-day rally of over 35% following the company's Q1 earnings beat on May 7. While the post-earnings bullishness receded over the subsequent two-week period however, the stock has bounced back this week with no constructive news flow, driving a short squeeze amid the over-extended bearishness. In the four-day period covered through Thursday, short interest as a percentage of free float on Bob's Discount was down from 24.6% to 20.6%, a 7-week low, with days-to-cover on the name also slipping from 5.8 to 4.9. In that time span, the stock was also up 16%, though shares of the discount furniture retailer are still down 19% year to date and down 20% from its IPO listing price in February.
Trade with 70% Backtested Accuracy
Analyst Views on TEM
About TEM
About the author

- Price Range Analysis: The ARKK ETF has a 52-week low of $62.945 and a high of $92.65, with the last trade at $82.55, indicating significant volatility and shifts in investor sentiment within the market.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides investors with valuable insights for technical analysis, aiding in the assessment of market trends and potential buy or sell opportunities.
- ETF Unit Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the fund.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify those experiencing notable inflows or outflows, as these liquidity shifts can significantly affect the performance of the underlying stocks held within the ETFs.
- Shareholder Sell-off Impact: Gray Media and Blue Media, linked to CEO Eric Lefkofsky, sold a combined 166,250 shares of Tempus AI Class A stock on Monday for approximately $9.6 million, with average prices between $55.38 and $59.23, raising concerns about potential negative market sentiment.
- Market Reaction: Despite a 6% rise in Tempus AI's stock on Wednesday, reaching its highest level in over five months, the stock slipped 0.4% late Monday following the sell-off announcement, indicating investor apprehension regarding the company's future, especially amid intensifying competition in the healthcare AI sector.
- Healthcare AI Outlook: A research firm noted that Tempus may be closer to the “AI as physician” thesis than any other publicly traded healthcare tech company, although the theme remains in its early stages and valuations are deemed “about right,” suggesting investors should proceed with caution.
- Research Collaboration Progress: Tempus's partnership with Angiosarcoma Awareness aims to leverage its dataset of 600 de-identified patient records to study a rare cancer diagnosed in about 1,000 individuals annually in the U.S., demonstrating the company's ongoing commitment and potential in the precision medicine space.
- SoundThinking Options Activity: SoundThinking Inc (Symbol: SSTI) has seen an options trading volume of 800 contracts today, representing approximately 80,000 shares, which accounts for 62.1% of its average daily trading volume over the past month, indicating heightened market interest in its future performance.
- High Volume Put Options: Within SSTI, the $7.50 strike put option has been particularly active, with 799 contracts traded today, representing about 79,900 shares, reflecting investor expectations regarding potential downside risks for the stock.
- SELLAS Options Activity: SELLAS Life Sciences Group Inc (Symbol: SLS) has recorded an options trading volume of 50,636 contracts today, equating to approximately 5.1 million shares, or 61.3% of its average daily trading volume over the past month, showcasing strong market interest in its stock.
- High Volume Call Options: For SLS, the $15 strike call option has seen a trading volume of 3,278 contracts today, representing around 327,800 shares, indicating investor confidence in the stock's potential for future gains.
- Research Collaboration Initiated: Tempus AI has partnered with Angiosarcoma Awareness, Inc. to leverage approximately 600 de-identified angiosarcoma records, aiming to accelerate research on this rare cancer, which is expected to significantly enhance understanding of angiosarcoma biology and advance precision medicine.
- Data Resource Integration: This collaboration will integrate Tempus' multimodal molecular and clinical data to help researchers identify biological patterns and potential therapeutic opportunities, thereby overcoming challenges in rare cancer research related to data fragmentation and lack of effective pre-clinical models.
- Enhanced Patient Engagement: The collaboration builds on the Angiosarcoma Project launched in 2017, aiming to directly involve patients and families in angiosarcoma research, enhancing patient voices and participation in scientific discovery.
- Commitment to Precision Medicine: Tempus' Chief Medical Officer, Ezra Cohen, emphasized that precision medicine should not be limited by data availability, and this collaboration will provide better treatment options for rare cancer patients, reflecting the company's strong commitment to advancing precision medicine.

- Growing Market Demand: The 2026 World Heart Report indicates that congenital heart disease now affects approximately 16 million people globally, up from 11.8 million three decades ago, highlighting the urgent need for advanced diagnostic technologies, particularly in low-income regions.
- Technological Innovation: Ventripoint's VMS+™ platform utilizes artificial intelligence to convert standard 2D echocardiograms into highly accurate 3D heart models, delivering MRI-level measurement accuracy to address the limitations of traditional imaging techniques in complex anatomical structures.
- Global Collaboration: Ventripoint announced its support for the newly formed Global Congenital Heart Disease Alliance (GCHDA) and plans to provide four VMS+™ units to directly support congenital heart disease patients, thereby expanding access to advanced diagnostic care.
- Broad Market Prospects: The echocardiography market is projected to reach approximately $2.64 billion by 2030, positioning Ventripoint favorably in the rapidly growing medical technology sector, especially as AI-driven cardiac imaging technologies gain increasing attention.
- FDA Approval: Tempus AI's ECG software received FDA clearance in 2024 for predicting the risk of atrial fibrillation (AF) in patients aged 65 and older, marking a significant advancement in the field of precision medicine.
- Multi-Center Validation Study: The study evaluated 4,017 patients across three distinct clinical sites, demonstrating that the ECG-AI risk score exceeded pre-specified performance thresholds, indicating the technology's reliability in diverse clinical environments and potentially transforming early risk detection in cardiac care.
- Clinical Application Potential: Findings suggest that the Tempus ECG-AF software can assist clinicians in identifying hidden AF risks earlier, thereby helping to minimize serious complications such as stroke and heart failure, ultimately enhancing overall patient care quality.
- Technological Innovation: The Tempus ECG-AF is the first FDA-cleared ECG-AI device designed to analyze 12-lead ECG recordings to detect early signs of AF, further advancing the company's technological development in the cardiovascular disease sector.







